Enhanced antitumour immunity following neoadjuvant chemoradiotherapy mediates a favourable prognosis in women with resected pancreatic cancer
CWF van Eijck, DAM Mustafa, D Vadgama… - Gut, 2024 - gut.bmj.com
Background This study investigates sex disparities in clinical outcomes and tumour immune
profiles in patients with pancreatic ductal adenocarcinoma (PDAC) who underwent upfront …
profiles in patients with pancreatic ductal adenocarcinoma (PDAC) who underwent upfront …
Spatial genomics reveals a high number and specific location of B cells in the pancreatic ductal adenocarcinoma microenvironment of long-term survivors
HM Aziz, L Saida, W de Koning, AP Stubbs… - Frontiers in …, 2023 - frontiersin.org
Background and aim Only 10% of pancreatic ductal adenocarcinoma (PDAC) patients
survive longer than five years. Factors underlining long-term survivorship in PDAC are not …
survive longer than five years. Factors underlining long-term survivorship in PDAC are not …
Rintatolimod in Advanced Pancreatic Cancer Enhances Antitumor Immunity through Dendritic Cell–Mediated T-Cell Responses
CWF van Eijck, H El Haddaoui, S Kucukcelebi… - Clinical Cancer …, 2024 - AACR
Purpose: Amid the need for new approaches to improve survival in pancreatic ductal
adenocarcinoma (PDAC), immune-based therapies have garnered interest. Rintatolimod, a …
adenocarcinoma (PDAC), immune-based therapies have garnered interest. Rintatolimod, a …
[HTML][HTML] A multigene circulating biomarker to predict the lack of FOLFIRINOX response after a single cycle in patients with pancreatic ductal adenocarcinoma
CWF van Eijck, W de Koning, F van der Sijde… - European Journal of …, 2023 - Elsevier
Abstract Introduction 5-fluorouracil, folinic acid, irinotecan and oxaliplatin (FOLFIRINOX) is
promising in treating patients with pancreatic ductal adenocarcinoma. However, many …
promising in treating patients with pancreatic ductal adenocarcinoma. However, many …
The placental innate immune system is altered in early-onset preeclampsia, but not in late-onset preeclampsia
M Broekhuizen, E Hitzerd, TPP van den Bosch… - Frontiers in …, 2021 - frontiersin.org
Preeclampsia is a severe placenta-related pregnancy disorder that is generally divided into
two subtypes named early-onset preeclampsia (onset< 34 weeks of gestation), and late …
two subtypes named early-onset preeclampsia (onset< 34 weeks of gestation), and late …
Tumor lineage-specific immune response in brain metastatic disease: opportunities for targeted immunotherapy regimen?
S Najjary, JM Kros, W de Koning, D Vadgama… - Acta neuropathologica …, 2023 - Springer
Metastases in the brain are the most severe and devastating complication of cancer. The
incidence of brain metastasis is increasing. Therefore, the need of finding specific druggable …
incidence of brain metastasis is increasing. Therefore, the need of finding specific druggable …
Identifying molecular changes in early cervical cancer samples of patients that developed metastasis
V de Geus, PC Ewing-Graham, W de Koning… - Frontiers in …, 2022 - frontiersin.org
Cervical cancer is one of the most common cancers in women worldwide. Patients
diagnosed with early-stage cervical cancer have a good prognosis, however, 10-20% suffer …
diagnosed with early-stage cervical cancer have a good prognosis, however, 10-20% suffer …
[HTML][HTML] GATA6 identifies an immune-enriched phenotype linked to favorable outcomes in patients with pancreatic cancer undergoing upfront surgery
This study underscores GATA6's role in distinguishing classical and basal-like pancreatic
ductal adenocarcinoma (PDAC) phenotypes. Retrospective studies associate GATA6 …
ductal adenocarcinoma (PDAC) phenotypes. Retrospective studies associate GATA6 …
Analyzing Flow Cytometry or Targeted Gene Expression Data Influences Clinical Discoveries—Profiling Blood Samples of Pancreatic Ductal Adenocarcinoma …
W de Koning, CWF van Eijck, F van der Sijde, GJ Strijk… - Cancers, 2023 - mdpi.com
Simple Summary We investigated the immunological changes in the blood of pancreatic
ductal adenocarcinoma patients treated with a single cycle of FOLFIRINOX chemotherapy …
ductal adenocarcinoma patients treated with a single cycle of FOLFIRINOX chemotherapy …
Characterizing the tumor immune microenvironment of ependymomas using targeted gene expression profiles and RNA sequencing
W de Koning, FF Feenstra, FGJ Calkoen… - Cancer Immunology …, 2023 - Springer
Background Defining the tumor immune microenvironment (TIME) of patients using
transcriptome analysis is gaining more popularity. Here, we examined and discussed the …
transcriptome analysis is gaining more popularity. Here, we examined and discussed the …